Funding for this research was provided by:
Text and Data Mining valid from 2018-08-29
Received: 6 September 2017
Accepted: 15 August 2018
First Online: 29 August 2018
Ethics approval and consent to participate
: Ethics approval was obtained from the New England Institutional Review Board, Newton, MA. The data used in this study were de-identified and obtained from commercial sources. As a result, no administrative permission was required for this study.
: Not applicable.
: RII, WYC, RHB, and MSD are employees of Analysis Group, Inc., a consulting company, which received financial support from Pfizer in connection with this study. FV and YX were employees of the Analysis Group, Inc. at the time the study was completed. LW, JA, SM, MRC, and MT are employees of, and may hold stock in, Pfizer. PM lectures and/or participates in advisory boards for Astellas, AstraZeneca, Basilea, Cubist, Gilead, MSD, Parexel, Pfizer, Tetraphase, and The Medicines Company.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.